title: Outcome of acute prosthetic joint infections due to gram-negative bacilli treated with open debridement and retention of the prosthesis.
abstract: The aim of our study was to evaluate the outcome of acute prosthetic joint infections (PJIs) due to gram-negative bacilli (GNB) treated without implant removal. Patients with an acute PJI due to GNB diagnosed from 2000 to 2007 were prospectively registered. Demographics, comorbidity, type of implant, microbiology data, surgical treatment, antimicrobial therapy, and outcome were recorded. Classification and regression tree analysis, the Kaplan-Meier survival method, and the Cox regression model were applied. Forty-seven patients were included. The mean age was 70.7 years, and there were 15 hip prostheses and 32 knee prostheses. The median number of days from the time of arthroplasty was 20. The most frequent pathogens were members of the Enterobacteriaceae family in 41 cases and Pseudomonas spp. in 20 cases. Among the Enterobacteriaceae, 14 were resistant to ciprofloxacin, while all Pseudomonas aeruginosa isolates were susceptible to ciprofloxacin. The median durations of intravenous and oral antibiotic treatment were 14 and 64 days, respectively. A total of 35 (74.5%) patients were in remission after a median follow-up of 463 days (interquartile range, 344 to 704) days. By use of the Kaplan-Meier survival curve, a C-reactive protein (CRP) concentration of < or = 15 mg/dl (P = 0.03) and receipt of a fluoroquinolone, when all GNB isolated were susceptible (P = 0.0009), were associated with a better outcome. By use of a Cox regression model, a CRP concentration of < or = 15 mg/dl (odds ratio [OR], 3.57; 95% confidence interval [CI], 1.05 to 12.5; P = 0.043) and receipt of a fluoroquinolone (OR, 9.09; 95% CI, 1.96 to 50; P = 0.005) were independently associated with better outcomes. Open debridement without removal of the implant had a success rate of 74.5%, and the factors associated with good prognosis were a CRP concentration at the time of diagnosis < or = 15 mg/dl and treatment with a fluoroquinolone.
authors.affiliation: Department of Orthopaedics, Hospital Clínic of Barcelona, Barcelona 08036, Spain.
authors.forename: Juan C
authors.initials: JC
authors.lastname: Martínez-Pastor
authors.forename: Ernesto
authors.initials: E
authors.lastname: Muñoz-Mahamud
authors.forename: Félix
authors.initials: F
authors.lastname: Vilchez
authors.forename: Sebastián
authors.initials: S
authors.lastname: García-Ramiro
authors.forename: Guillem
authors.initials: G
authors.lastname: Bori
authors.forename: Josep
authors.initials: J
authors.lastname: Sierra
authors.forename: José A
authors.initials: JA
authors.lastname: Martínez
authors.forename: Lluis
authors.initials: L
authors.lastname: Font
authors.forename: Josep
authors.initials: J
authors.lastname: Mensa
authors.forename: Alex
authors.initials: A
authors.lastname: Soriano
mesh_terms: D000208:Acute Disease; D000368:Aged; D002097:C-Reactive Protein / Q000032:analysis; D003646:Debridement; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000097:blood / Q000401:mortality / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016459:Prosthesis-Related Infections / Q000097:blood / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D002097:C-Reactive Protein
references.citation: Clin Infect Dis. 2008 Apr 1;46(7):1009-14
references.pmid: 18444817
references.citation: Antimicrob Agents Chemother. 2003 Dec;47(12):3967-9
references.pmid: 14638511
references.citation: N Engl J Med. 2004 Aug 5;351(6):523-6
references.pmid: 15295041
references.citation: Antimicrob Agents Chemother. 2007 Apr;51(4):1556-8
references.pmid: 17220399
references.citation: Antimicrob Agents Chemother. 1995 Nov;39(11):2423-5
references.pmid: 8585720
references.citation: J Clin Microbiol. 2001 Dec;39(12):4468-71
references.pmid: 11724863
references.citation: Infection. 2004 Aug;32(4):222-8
references.pmid: 15293078
references.citation: Am J Med. 2006 Nov;119(11):993.e7-10
references.pmid: 17071171
references.citation: J Antimicrob Chemother. 2004 Mar;53(3):533-5
references.pmid: 14963066
references.citation: Antimicrob Agents Chemother. 2007 May;51(5):1656-60
references.pmid: 17353249
references.citation: Clin Microbiol Infect. 2006 Oct;12(10):1030-3
references.pmid: 16961643
references.citation: J Infect. 2007 Jul;55(1):1-7
references.pmid: 17343916
references.citation: JAMA. 1998 May 20;279(19):1537-41
references.pmid: 9605897
references.citation: Chemotherapy. 1999 Jan-Feb;45(1):28-36
references.pmid: 9876207
references.citation: N Engl J Med. 2004 Oct 14;351(16):1645-54
references.pmid: 15483283
references.citation: Clin Microbiol Infect. 2006 May;12(5):433-9
references.pmid: 16643519
references.citation: Clin Microbiol Infect. 2006 Sep;12(9):930-3
references.pmid: 16882303